BDX insider trading

NYSE Healthcare

BECTON DICKINSON & CO — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades
1,163
Last 90 days
11
Buys / sells
1% / 18%
Market cap
$67.53B

About BECTON DICKINSON & CO

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Company website: www.bd.com

BDX insider activity at a glance

FilingIQ has scored 1,163 insider transactions for BDX since Jan 12, 2015. The most recent filing in our index is dated May 8, 2026.

Across the full history, 6 open-market purchases and 213 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BDX insider trades is 59.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

Other Healthcare tickers with recent insider activity

13F funds holding BDX

Politicians who have traded BDX

Frequently asked

How many insider trades does FilingIQ track for BDX?
FilingIQ tracks 1,163 Form 4 insider transactions for BDX (BECTON DICKINSON & CO), covering filings from Jan 12, 2015 onwards. 11 of those were filed in the last 90 days.
Are BDX insiders net buyers or net sellers?
Across the full Form 4 history for BDX, 6 transactions (1%) were open-market purchases and 213 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BDX insider data come from?
Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BDX in?
BECTON DICKINSON & CO (BDX) is classified in the Healthcare sector, specifically Medical Instruments & Supplies, with a current market capitalisation of $67.53B.

Methodology & sources

Every BDX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.